Improved Synthesis Of Succinimides And Quaternary Ammonium Ions For Use In Making Molecular Sieves
US-2015329487-A1 · Nov 19, 2015 · US
US10322998B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10322998-B2 |
| Application number | US-94738210-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2010 |
| Priority date | Aug 26, 2002 |
| Publication date | Jun 18, 2019 |
| Grant date | Jun 18, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.
Opening claim text (preview).
What is claimed is: 1. An isolated, unnatural polypeptide compound comprising six or more residues, wherein each residue is independently selected from the group consisting of α-amino acid residues, β-amino acid residues, and γ-amino acid residues; wherein at least two of the residues are one each of a β-amino acid residue and a γ-amino acid residue, wherein one of the β-amino acid residue or the γ-amino acid residue is cyclically-constrained in a monocyclic or bicyclic C 4 to C 10 cycloalkyl ring; wherein at least one of the residues is an α-amino acid residue, and the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof and N-alkylated derivatives thereof; and wherein the polypeptide comprises an N-terminus. 2. The compound of claim 1 , wherein the N-terminus comprises an N-terminal residue, the N-terminal residue is one of the six or more residues, and the N-terminal residue comprises a free amino group, a protonated amino group, or an amino group protected with an amino-terminus protecting group. 3. The compound of claim 2 , wherein the amino-terminus protecting group is selected from the group consisting of methyl, formyl, ethyl, acetyl, t-butyl, benzyl, trifluoroacetyl, t-butoxycarbonyl, benzoyl, 4-methylbenzyl, benzyloxymethyl, 4-nitrophenyl, benzyloxycarbonyl, 2-nitrobenzoyl, 2-nitrophenylsulphenyl, 4-toluenesulphonyl, pentafluorophenyl, diphenylmethyl, 2-chlorobenzyloxycarbonyl, 2,4,5-trichlorophenyl, 2-bromobenzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, triphenylmethyl, and 2,2,5,7,8-pentamethyl-chroman-6- sulphonyl. 4. The compound of claim 1 , wherein one or more of the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof and N-alkylated derivatives thereof. 5. An isolated, unnatural polypeptide compound comprising six or more residues, wherein each residue is independently selected from the group consisting of α-amino acid residues, β-amino acid residues, and γ-amino acid residues; wherein at least two of the residues are one each of a β-amino acid residue and a γ-amino acid residue, wherein one of the β-amino acid residue or the γ-amino acid residue is cyclically-constrained in a monocyclic or bicyclic C 4 to C 10 cycloalkyl ring; and wherein at least one of the residues is an α-amino acid residue, and the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof and N-alkylated derivatives thereof; wherein one or more of the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof and N-alkylated derivatives thereof. 6. An isolated, unnatural polypeptide compound selected from the group consisting of: wherein: each X and each Z is independently variable and is selected from the group consisting of α-amino acid residues, β-amino acid residues, and γ-amino acid residues, provided that at least one X or Z comprises an α-amino acid residue and at least another two of X or Z comprise two cyclically-constrained γ-amino acid residues; the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof, and N-alkylated derivatives thereof; one or more of the at least one α-amino acid residue is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, nor-valine, nor-leucine, ornithine, hydroxylated derivatives thereof, and N-alkylated derivatives thereof; each cyclically-constrained γ-amino acid residue is independently selected from the group consisting of: R, together with the carbons to which it is attached, and further together with the β-position carbon in the γ-amino acid backbone where appropriate, independently defines a substituted or unsubstituted, monocyclic or bicyclic C 4 to C 10 cycloalkyl or cycloalkenyl moiety, provided that, in at least one of the cyclically-constrained γ-amino acid residues, R, together with the carbons to which it is attached, and further together with the β-position carbon in the γ-amino acid backbone where appropriate, defines a substituted or unsubstituted, monocyclic or bicyclic C 4 to C 10 cycloalkyl moiety; each “Y” is independently variable and is a single bond or a reverse-turn moiety; “A” is independently selected from the group consisting of hydrogen and an amino-terminus protecting group, and “A′” is selected from the group consisting of hydroxyl and a carboxy-terminus protecting group; and each “a,” “c,” and “d” is an independently variable positive integer; and “a”+“c”>3; and salts thereof. 7. The compound of claim 6 , wherein at least one R, together with the carbons to which it is attached and together with a β-position carbon in the γ-amino acid backbone when the β-position carbon is present, independently defines a substituted C 5 to C 6 cycloalkyl or cycloalkenyl moiety; and substituents on the cycloalkyl or cycloalkenyl moieties are independently selected from the group consisting of linear, branched, or cyclic C 1 -C 6 -alkyl, alkenyl, or alkynyl; mono- or bicyclic aryl, mono- or bicyclic heteroaryl having up to 5 heteroatoms selected from N, O, and S; mono- or bicyclic aryl-C 1 -C 6 -alkyl, mono- or bicyclic heteroaryl-C 1 -C 6 -alkyl, —(CH 2 ) n+1 —OR 2 , —(CH 2 ) n+1 —SR 2 , —(CH 2 ) n+1 —S(═O)—CH 2 —R 2 , —(CH 2 ) n+1 —S(═O) 2 —CH 2 —R 2 , —(CH 2 ) n+1 —NR 2 R 2 , —(CH 2 ) n+1 —NHC(═O)R 2 , —(CH 2 ) n+1 —NHS(═O) 2 —CH 2 —R 2 , —(CH 2 ) n+1 —O—(CH 2 ) m —R 1 , —(CH 2 ) n+1 —S—(CH 2 ) m —R 1 , —(CH 2 ) n+1 —S(═O) 2 —(CH 2 ) m —R 1 2 , —(CH 2 ) n+1 —S(═O) 2 —(CH 2 ) m —R 1 , —(CH 2 ) n+1 —NH—(CH 2 ) m —R 1 , —(CH 2 ) n+1 —N—{(CH 2 ) m —R 1 } 2 , —(CH 2 ) n+1 —NHC(═O)—(CH 2 ) n+1 —R 1 , —(CH 2 ) n+1 —NHS(═O) 2 —(CH 2 ) m —R 1 , —(CH 2 ) n —OR, —(CH 2 ) n —SR 2 , —(CH 2 ) n —S(═O)—CH 2 —R 2 , —(CH 2 ) n —S(═O) 2 —CH 2 —R 2 , —(CH 2 ) n —NR 2 R 2 , —(CH 2 ) n —NHC(═O)R 2 , —(CH 2 ) n —NHS(═O) 2 —CH 2 —R 2 , —(CH 2 ) n —O—(CH 2 ) m —R 1 , —(CH 2 ) n —S—(CH 2 ) m —R 1 , —(CH 2 ) n —S(═O)—(CH 2 ) m —R 1 , —(CH 2 ) n —S(═O) 2 —(CH 2 ) m —R 1 , —(CH 2 ) n NH—(CH 2 )
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
The ring being saturated · CPC title
the ring being saturated · CPC title
Sulfur atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.